These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 32407673)

  • 21. Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy.
    Duan YC; Zhang SJ; Shi XJ; Jin LF; Yu T; Song Y; Guan YY
    Eur J Med Chem; 2021 Oct; 222():113588. PubMed ID: 34107385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetics in cancer stem cells.
    Toh TB; Lim JJ; Chow EK
    Mol Cancer; 2017 Feb; 16(1):29. PubMed ID: 28148257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics.
    Duan YT; Sangani CB; Liu W; Soni KV; Yao Y
    Curr Top Med Chem; 2019; 19(12):972-994. PubMed ID: 31161992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting Cancer through the Epigenetic Features of Telomeric Regions.
    Vaquero-Sedas MI; Vega-Palas MÁ
    Trends Cell Biol; 2019 Apr; 29(4):281-290. PubMed ID: 30660503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetics: Reading the second genomic code.
    Marx V
    Nature; 2012 Nov; 491(7422):143-7. PubMed ID: 23128234
    [No Abstract]   [Full Text] [Related]  

  • 26. Chromatin engineering offers an opportunity to advance epigenetic cancer therapy.
    Baskin NL; Haynes KA
    Nat Struct Mol Biol; 2019 Oct; 26(10):842-845. PubMed ID: 31582843
    [No Abstract]   [Full Text] [Related]  

  • 27. Targeting histone modifications--epigenetics in cancer.
    Waldmann T; Schneider R
    Curr Opin Cell Biol; 2013 Apr; 25(2):184-9. PubMed ID: 23347561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The growing role of epigenetics in childhood cancers.
    Panditharatna E; Filbin MG
    Curr Opin Pediatr; 2020 Feb; 32(1):67-75. PubMed ID: 31895160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic Targeting of
    Huang M; Zeki J; Sumarsono N; Coles GL; Taylor JS; Danzer E; Bruzoni M; Hazard FK; Lacayo NJ; Sakamoto KM; Dunn JCY; Spunt SL; Chiu B
    Cancer Res; 2020 Mar; 80(5):1024-1035. PubMed ID: 31900258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
    Li X; Song Y
    J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers.
    Chabanon RM; Morel D; Postel-Vinay S
    Semin Cancer Biol; 2020 Apr; 61():180-198. PubMed ID: 31568814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. German-Catalan workshop on epigenetics and cancer.
    Vizoso M; Esteller M
    Epigenetics; 2013 Sep; 8(9):998-1003. PubMed ID: 23884202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results.
    Pasini A; Delmonte A; Tesei A; Calistri D; Giordano E
    Drugs; 2015 Oct; 75(15):1757-71. PubMed ID: 26347133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted Protein Degradation as a Promising Tool for Epigenetic Upregulation of Fetal Hemoglobin.
    J Verheul TC; Trinh VT; Vázquez O; Philipsen S
    ChemMedChem; 2020 Dec; 15(24):2436-2443. PubMed ID: 33002296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting chromatin.
    Nat Struct Mol Biol; 2019 Oct; 26(10):841. PubMed ID: 31582845
    [No Abstract]   [Full Text] [Related]  

  • 36. Drugging Chromatin in Cancer: Recent Advances and Novel Approaches.
    Cai SF; Chen CW; Armstrong SA
    Mol Cell; 2015 Nov; 60(4):561-70. PubMed ID: 26590715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploiting tumor vulnerabilities: epigenetics, cancer metabolism and the mTOR pathway in the era of personalized medicine.
    Muñoz-Pinedo C; González-Suárez E; Portela A; Gentilella A; Esteller M
    Cancer Res; 2013 Jul; 73(14):4185-9. PubMed ID: 23687347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chromatin dependencies in cancer and inflammation.
    Marazzi I; Greenbaum BD; Low DHP; Guccione E
    Nat Rev Mol Cell Biol; 2018 Apr; 19(4):245-261. PubMed ID: 29184195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of epigenetics in kidney cell biology.
    Li LX; Agborbesong E; Zhang L; Li X
    Methods Cell Biol; 2019; 153():255-278. PubMed ID: 31395383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospects for the development of epigenetic drugs for CNS conditions.
    Szyf M
    Nat Rev Drug Discov; 2015 Jul; 14(7):461-74. PubMed ID: 26000723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.